Mutual of America Capital Management LLC Sells 1,424 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mutual of America Capital Management LLC lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,475 shares of the pharmaceutical company’s stock after selling 1,424 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $15,260,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $3,731,000. FIL Ltd lifted its holdings in Vertex Pharmaceuticals by 1,226.6% during the 4th quarter. FIL Ltd now owns 93,273 shares of the pharmaceutical company’s stock worth $37,561,000 after purchasing an additional 86,242 shares during the last quarter. Azimuth Capital Investment Management LLC lifted its holdings in Vertex Pharmaceuticals by 3.3% during the 4th quarter. Azimuth Capital Investment Management LLC now owns 22,141 shares of the pharmaceutical company’s stock worth $8,916,000 after purchasing an additional 697 shares during the last quarter. Finally, DRW Securities LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at $479,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VRTX. Royal Bank Of Canada decreased their price target on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. boosted their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research note on Monday, July 14th. Canaccord Genuity Group dropped their price target on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research note on Wednesday. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, UBS Group set a $553.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday. Thirteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $497.10.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $385.65 on Thursday. The firm has a market capitalization of $99.03 billion, a price-to-earnings ratio of 27.57 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52-week low of $372.35 and a 52-week high of $519.88. The stock has a fifty day moving average of $453.73 and a 200 day moving average of $466.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.52.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($12.83) EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.